Skip to content
Screener

CG Oncology CGON Q2 2025 earnings

Reported August 8, 2025 · Before market open

Revenue-
EPS-$0.54Miss by $0.05
EPS estimate-$0.49

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$547.7K
EPS estimate-$0.86

Financials

Q2 2025

Income statement

See full
Revenue--100%
Operating income-$48.7M-88.5%
Net income-$41.4M-119%
EPS (diluted)-$0.54-92.9%

Balance sheet

See full
Cash & equivalents$14.6M-41.9%
Total debt$994.0K+180%
Total equity$670.4M+21.4%
Total assets$701.4M+24.3%

Cash flow

See full
Operating cash flow-$28.0M-73.4%
CapEx$14.0K0.0%
Free cash flow-$28.0M-73.4%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.97B-6.5%
Enterprise value$1.95B-6.1%
P/S3,569.2×+332×

Profitability

See full
Operating margin-28,546.1%-134,056pp
Net margin-23,245.2%-88,727pp
FCF margin-17,069.9%—

Returns & leverage

See full
Return on equity-21%—
Debt / equity0×0.0×
Current ratio22.2×-25.4×

Segments

By product

See full
Commercial And Development Revenue-—
License And Collaboration Revenue-—

FAQ

When did CG Oncology report Q2 2025 earnings?
CG Oncology (CGON) reported Q2 2025 earnings on August 8, 2025 before market open.
What were CG Oncology's Q2 2025 revenue and EPS?
CG Oncology reported revenue of - and eps of $-0.54 for Q2 2025.
Did CG Oncology beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.49 by $0.05.
How did CG Oncology's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $111.0K a year earlier and eps declined 92.9% from $-0.28.
Where can I find CG Oncology's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-105487) and the 10-Q periodic report (0000950170-25-105855) directly on SEC EDGAR. The filing index links above go to sec.gov.